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Abstract
Background
The role of nipple discharge cytology (NDc) in the surgical management of breast cancer
patients is unclear. We aimed: (i) to evaluate the effect of malignant NDc on the surgical
approach to the nipple-areola complex, and (ii) to verify the association between malignant
NDc and nipple malignancy.
Methods
We retrospectively analyzed a case series of 139 patients with NDc who underwent breast
surgery. The clinical and histological findings, types of surgery with emphasis on nipple-are-
ola complex amputation, immunohistochemical phenotypes of the carcinomas and mea-
surements of the tumor-nipple distance were recorded. Additionally, in patients who showed
HER2-positive lesions on definitive surgery, we evaluated the HER2 immunocytochemistry
of the NDc smears.
Results
Thirty-two malignant and 107 benign/borderline NDc diagnoses were identified. All 32 malig-
nant-NDc cases were histologically confirmed as malignant. Thirty borderline/benign-NDc
cases were histologically diagnosed as malignant (sensitivity 58%). The majority of the
patients with malignant NDc were treated with nipple-areola complex amputations in both
the mastectomy and conservative surgery groups (P<0.001, χ251.77). Nipple involvement
was strongly associated with HER2-positive ductal carcinoma in-situ (P<0.001, χ211.98).
HER2 immunocytochemistry on the NDc revealed a 100% correlation with the immunocyto-
chemistry performed on the surgical tissues.
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Conclusions
Malignant NDc influenced surgical management. The association of malignant NDc with nip-
ple involvement is highly related to ductal carcinoma in-situ with HER2 overexpression. In
case of HER2 positive NDc, nipple-areola complex involvement is more likely than in HER2
negative cases.
Introduction
Nipple discharge (ND) accounts for approximately 5% of breast-related symptoms [1] and is
the third most common reason women seek medical attention, following breast lumps and
breast pain [2]. Hormonal diseases, such as hypo and hyperthyroidism and prolactinoma [1,
2], generally cause bilateral ND. In contrast, the majority of unilateral ND cases result from a
breast disease, such as intraductal papilloma, duct ectasia or plasma cell mastitis. In addition,
approximately 7% to 15% [2] of unilateral NDs are caused by malignant lesions, primarily duc-
tal carcinoma in-situ (DCIS) [2–4] with micropapillary features in which the cells detach in
the ducts and flow into the nipple [5]. ND has been classified based on its appearance as milky,
yellow, watery, pink or bloody [6, 7]. A meta-analysis demonstrated that bloody ND is a pre-
dictor of breast cancer (BC) risk [7]. The role of the cytological results of ND samples in the
planning of surgical approaches for patients remains unsettled. Some authors consider it
together with clinical and radiological assessment as a diagnostic evaluation of the risk of
underlying carcinoma [8], however others recommend to exclude ND cytology (NDc) from
the diagnostic algorithms of breast diseases to avoid confusion in patient surgical management
[9], whereas others include it but do not give recommendations in case of malignant NDc
results [10]. As a matter of fact, the cytological diagnosis of ND may be difficult because the
quality of smears may be poor and the number of diagnostic cells may be low, leading to low
sensitivity of the procedure [11–13]. On the other hand, the diagnosis of malignant NDc is
highly specific (97 to 100%) [12–14]. Few studies are available on the use of NDc results to
address surgical techniques on the nipple-areolar complex (NAC). Discouraging results have
been published by Cabioglu N et al. [15] and Chang and Cheung [16] on the use of ND as a
marker of NAC involvement, however in both studies few cases were examined by NDc and
the majority were within the benign category [16]. Nevertheless, new surgical techniques that
improve cosmetic results, such as nipple-sparing breast surgery [17–19], require additional
information about the presence of occult tumor cells at the NAC site. For example, Paget’s dis-
ease of the nipple may be silent at both, clinical examination and radiological imaging.
The Italian Guidelines for nipple sparing mastectomy [20] consider the distance between
the lesion and the NAC as the most important parameter for NAC preservation or amputation.
In addition, one of the absolute contraindications for nipple preservation is malignant NDc.
Thus, in clinical practice it remains uncertain whether this data may be relevant for surgical
approach.
Considering this complex background, the aim of this study was twofold: (i) to determine
the correlation between malignant NDc and surgical approach to NAC in our retrospective
case series; and (ii) to verify the association between malignant NDc and presence of malig-
nancy in less than 2 cm from NAC.
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Materials and methods
We retrospectively selected a series of 139 patients with NDc who underwent surgical breast
resection at the Breast Unit of Città della Salute e della Scienza, Molinette Hospital and
St. Anna Hospital, Turin, Italy from January 2010 to December 2015.
In our Breast Unit, NDc are smeared on two or more slides, which are then air dried and
stained with Giemsa. For the study purposes, the ND smears were re-examined by two pathol-
ogists who were blinded to the original cytological diagnosis. The samples were classified in
three categories: malignant (cancer cells in the smear), borderline (atypical clusters of epithelial
cells disposed in papillary structures and/or sporadic epithelial morulae) and benign (presence
of histiocytes, amorphous material, but no epithelial cells). Data regarding ND appearance
(bloody vs not bloody, mono or pluri-ductal involvement, spontaneous or induced) were col-
lected together with imaging data (i.e. US, mammography and quadrant involvement) and
type of surgery (conservative vs mastectomy) (Table 1).
Table 1. Clinical and imaging data at presentation of patients with nipple discharge cytology (NDc).
NDc Benign
62 (45%)
Borderline
45 (32%)
Malignant
32 (23%)
Total
139
P value
Age (years)
<40 6 (60%) 1 (10%) 3 (30%) 10 0.01
40–50 16 (53%) 6 (20%) 8 (27%) 30
51–70 30 (45,5%) 28 (42,5%) 8 (12%) 66
>70 10 (30%) 10 (30%) 13 (40%) 33
Color
Bloody 33 (37%) 32 (35%) 25 (28%) 90 0.06
Serous 25 (64%) 9 (23%) 5 (13%) 39
Others (Serous, Milky or Yellow) 4 (40%) 4 (40%) 2(20%) 10
Ductal Involvement
Mono-ductal 54 (44%) 41 (33%) 28 (23%) 123 0.79
Pluri-ductal 8 (50%) 4 (25%) 4 (25%) 16
Presentation
Spontaneous 54 (45%) 41 (34%) 26 (21%) 121 0.44
Induced 8 (44,5%) 4 (22%) 6 (33,5%) 18
Mammography
Positive (R4/R5) 18 (36%) 5 (10%) 27 (54%) 50 <0.001
Doubt (R3) 22 (61%) 13 (36%) 1 (3%) 36
Negative (R1/R2) 22 (41%) 27 (51%) 4 (8%)* 53
Ultrasound
Positive (U4/U5) 17 (34%) 5 (10%) 28 (56%) 50 <0.001
Doubt (U3) 24 (58%) 16 (39%) 1 (3%) 41
Negative (U1/U2) 21 (44%) 24 (50%) 3 (6%) 48
Quadrant involvement
Central quadrant 38 (41%) 39 (43%) 15 (16%) 92 <0.001
Others 24 (51%) 6 (13%) 17 (36%) 47
Type of surgery
Mastectomy 7 (28%) 0 18 (72%) 25 <0.001
Conservative 55 (48.5%) 45 (39.5%) 14 (12%) 114
*three out four patients were negative for both Mammography and Ultrasound.
https://doi.org/10.1371/journal.pone.0182073.t001
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The surgical specimens of patients with ND were re-examined and the lesions were classi-
fied as benign (papillary/hyperplastic lesions) and malignant (in-situ/invasive cancers). We re-
assessed their size and histological type. In case of malignancy, immunophenotype (ER, PR,
HER2 and KI67) was obtained from diagnostic report. According to the local protocol, NAC
surgical specimen is analyzed on at least two different paraffin embedded blocks. For the study
purposes, we evaluated 5 extra hematoxylin-eosin stained sections from each block to better
define the distance from the lesion to the tip of the nipple. Taking into account the minimal
distance recommended by guidelines for considering nipple-sparing surgical approach [20],
we considered involvement of NAC when the lesion was2 cm from the tip of the nipple
either in the form of intraductal spreading or of stromal invasion. Ethical approval for this
study was obtained from the Comittee for human Biospecimen Utilization (Department of
Medical Sciences -ChBU). The project provided a verbal and not written informed consent,
obtained at the time of surgery, from the patients due to the retrospective approach of the
study, which did not impact on their treatment. The procedure for collecting verbal consent
was approved by the Committee for human Biospecimen Utilization (Department of Medical
Sciences -ChBU). All the cases were anonymously recorded and data were accessed
anonymously.
Immunohistochemistry of NDc
In the cases of HER2-positive malignant lesions at the definitive surgery, considering that
HER2 is the biomarker used to highlight the presence of cancer cells in nipple-areola area [21–
25], we evaluated the HER2 status of the corresponding ND smears. Specifically, one slide for
each case was de-mounted, and endogenous peroxidase was blocked by incubation with 6%
H2O2. The slides were then incubated with the primary antibody included in the HercepTest™
(Dako, Glostrup, Denmark) for 30 minutes at room temperature. After washing, the slides
were incubated with Dako EnVision™Systems solution. The reaction was developed in a solu-
tion containing 3,3’diaminobenzidine (LiquidDAB Substrate Pack, BioGenex. Freemont, Ca).
HER2 intensity was scored following ASCO/CAP guidelines [26] and NDc were considered as
positive if an intense to moderate HER2 staining was present on the membrane of at least ten
morphologically malignant cells.
As controls of the specificity of HER2, immunocytochemical (ICC) reaction, 3 negative and
5 borderline ND smears, which were not correlated with malignancy on NAC histological
specimens, were stained following the same procedure.
In addition, two air dried smears stained with Giemsa of HER2-positive BT474 and HER2-
negative MCF7 BC cell lines were prepared and one week later were demounted and were pro-
cessed as above reported.
Statistical analysis
Statistical analyses were performed using contingency tables (Chi Square test and Fisher Exact
test). The statistically significant probability value was set at P<0.05. We calculated at that
point the sensitivity, specificity and positive (PPV) and negative (NPV) predictive values of the
NDc.
Results
As shown in Table 1, of the 139 NDc smears, 32 were malignant, 45 were borderline, and 62
were benign. In the majority of patients, ND was bloody, spontaneous and mono-ductal.
Malignant NDc correlated with a high suspect of breast malignancy at ultrasound and/or
mammography examination (P<0.001). DCIS were detected in 3 patients studied by magnetic
Malignant NDc and breast cancer surgical approach
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resonance with malignant NDc and negative mammography and ultrasound results. Two of
these were DCIS with micropapillary features and one was a solid DCIS with intra-ductal
papilloma.
The correlation between NDc and histological diagnosis of surgical specimens confirmed
that 100% of malignant NDc were related to an in-situ and/or invasive carcinoma. Otherwise,
only 28% (30/107) of benign/borderline NDc were related to malignancy. In the remaining
72% (77/107) of cases a papillary or hyperplastic intraductal proliferation was diagnosed
(Table 2).
The specificity and the PPV of NDc were 100% with a sensitivity of 58% and a NPV of 63%.
The malignant lesions were generally larger in the cases with malignant NDc (P<0.001)
(Table 3).
Correlation between malignant NDc and surgical approach to NAC
Fig 1 provides a summary of the NDc results, surgical approach and NAC status at histology.
Of the 32 patients with malignant NDc, in 22 cases NAC amputation was performed, 17 dur-
ing mastectomy and 5 during conservative surgery with central quadrant excision. On the
other hand, in borderline/benign NDc, NAC amputation was performed in all cases with mas-
tectomy and in 2/81 central quadrant excision surgeries (Fig 1A). Approximately, 70% of the
patients (22/32) with malignant NDc and 8.4% (9/107) with benign/borderline NDc were
treated with NAC amputation (P<0.001).
Table 2. Correlation between NDc and histological diagnosis of surgical specimens.
ND Cytology P value
Total
139
Benign+Borderline
107
Malignant
32
Histological diagnosis
Malignant 62 (45%) 30 (28%) 32 (100%) < 0.001
DCISa 29 12 17
DCIS and ICb 22 10 12
ICb 11 8 3
Non malignant 77 (55%) 77 (72%) 0
Benign Lesion 41 41 /
Papillary Lesion 36 36 /
aDCIS: ductal carcinoma in-situ.
bIC: Invasive carcinoma.
https://doi.org/10.1371/journal.pone.0182073.t002
Table 3. Correlation between NDc and histological size of surgical specimens.
ND Cytology P value
Size of lesion Benign /Borderline
107
Malignant
32
<20 mm 85 12 < 0.001
20–30 mm 13 8
>30 mm 2 10
Multicentric 2 2
https://doi.org/10.1371/journal.pone.0182073.t003
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Association between malignant NDc and presence of malignancy in less
than 2 cm from NAC
To clarify whether a malignant NDc per se might have a role in the selection of patients who
require NAC amputation, we analyzed in detail the specimens of the 31 patients (24 mastec-
tomy and 7 conservative surgery) undergoing this surgical procedure (Fig 1A) and correlated
it with the NDc results and histological characteristics (Table 4).
Of the 31 patients with NAC amputation, 14 had NAC involved by DCIS and/or invasive
cancer (Fig 2A) and 13 of these had a malignant NDc (P 0.014) (Fig 2B).
HER2 was overexpressed (score 3+) in 9 cases. All of these were DCIS (Fig 2C), growing
within lactiferous ducts of the subareolar region and/or the nipple and showing malignant
NDc. The immunostaining of the corresponding NDc smears demonstrated that the malig-
nant cells overexpressed HER2 as well (Table 4) (Fig 2D). In the subset of 17 cases without
NAC involvement, only 1 (6%) invasive cancer exhibited HER2 overexpression (P<0.001);
however, both the associated DCIS and the corresponding NDc were HER2-negative. HER2
membrane expression was not detected on epithelial cells of negative and suspicious NDc
smears. The immunostaining performed as control confirmed MCF-7 cells as negative for
HER2 overexpression (Fig 3A), while BT474 cells showed a positive membrane staining, but
some granules were immunostained within the cell cytoplasm as well (Fig 3B).
Discussion
Some studies suggest that NDc should not be considered in the management of patients [10, 9]
because, although its high specificity, it shows a low sensitivity [13, 14]. In the present study,
we confirmed the low sensitivity of non-malignant NDc (28% had an underlying malignant
lesion). On the other hand, we confirmed the high specificity of malignant NDc, that was dem-
onstrated by the presence of an in-situ and/or an invasive carcinoma at definitive surgery in all
patients. We than wanted to verify the association between malignant NDc and the real pres-
ence of cancer in the nipple area. We found that 13/14 cases with NAC involvement presented
malignant NDc.
Fig 1. Nipple discharge cytology (NDc). Summary of results, types of surgery and nipple areola complex
(NAC) involvement at histology.
https://doi.org/10.1371/journal.pone.0182073.g001
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Table 4. Pathology data of the malignant breast lesions of patients who underwent nipple-areola complex (NAC) amputation.
NAC involved
14 (45%)
NAC free
17 (55%)
Total
31
P Value
NDca 0.014
Malignant 13 9 22
Benign/Borderline 1 8 9
Type of lesion 0.90
DCISb 6 6 12
DCIS + ICc 6 10 16
Invasive carcinoma 2 1 3
Histological Grade of ICc 0.44
1 3 3 6
2 0 4 4
3 5 4 9
Histological type of DCISd 0.91
Micropapillary 5 7 12
Papillary 3 3 6
Cribriform 1 1 2
With comedonecrosis 3 5 8
Nuclear grade of DCISe 0.76
Low 0 1 1
Intermediate 2 3 5
High 4 2 6
HER2 on histological specimens <0.001
Positive 9 1* 10
Negative 5 16 21
Estrogen Receptor 0.76
>1 11 15 26
0 3 2 5
Progesterone Receptor 0.62
>1 4 7 11
0 2 1 3
Not Known 8 9 17
Size of cancer at histology 0.94
<20 mm 5 6 11
20–30 mm 4 7 11
>30 mm 5 4 9
HER2 on malignant NDc <0.001
Positive 9 0 9
Negative 5 17 22
aNDc: nipple discharge cytology;
bDCIS: ductal carcinoma in-situ;
cIC: invasive carcinoma;
dDCIS both as single lesion or associated at invasive carcinomas;
eDCIS as pure lesion;
*HER2 was positive only in the infiltrating carcinoma.
https://doi.org/10.1371/journal.pone.0182073.t004
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Moreover, in agreement with others [27], we showed that malignant NDc was frequently
correlated with large breast cancers primarily located in the central quadrant.
In clinical practice, there is no consensus regarding the surgical approach to patients with
malignant cells on NDc. However, the data we obtained from a retrospective cohort of patients
revealed that the majority of cases with malignant NDc underwent NAC amputation irrespec-
tive of the type of surgery performed (i.e., mastectomy or conservative surgery). These data
suggest that malignant NDc diagnosis may influence surgeons in their clinical practice.
We are aware that our case series is small to draw definitive conclusions, however, our find-
ings are in line with previous works, showing that in-situ carcinomas are the primary cause of
NAC involvement and that these DCIS frequently overexpress HER2 [28–30, 25]. Bauer et al.
[27] showed that when ND is the result of DCIS, in 63% of the cases the central location and
Fig 2. Giemsa staining & ICC. Giemsa staining on ND smear (A) and on the corresponding DCIS (B). HER2
ICC expression of the malignant cells on ND smear (C) and on the corresponding DCIS (D).
https://doi.org/10.1371/journal.pone.0182073.g002
Fig 3. HER2 expression in BC cell lines. Immunohistochemistry for MCF7 (A) and BT474 (B) cells.
https://doi.org/10.1371/journal.pone.0182073.g003
Malignant NDc and breast cancer surgical approach
PLOS ONE | https://doi.org/10.1371/journal.pone.0182073 August 14, 2017 8 / 11
the intraductal spreading of cells may preclude breast conserving surgery. In a previous study
on micropapillary DCIS, we have demonstrated that this growth pattern may represent a risk
factor for local recurrence after breast-conserving surgery and that patient may suffer of spon-
taneous ND [5], positive at cytology examination. In the present study, we observed that
micropapillary and papillary DCIS histotype are frequently related to ND, although this associ-
ation was not specific of NAC involvement (Table 4).
The rate of occult NAC involvement reported in patients with invasive BC, is highly vari-
able (from 0% to 27%) [31, 32, 18, 33] and mammographic distance between tumor and nip-
ple, axial tumor-NAC distance at magnetic resonance imaging [31, 32], tumor size, pathologic
staging [34, 35] and HER2 amplification [33] have been proposed to predict NAC status. The
Italian Guidelines for nipple sparing mastectomy [20] consider the distance between the lesion
and the NAC evaluated using imaging analysis as the most important parameter for NAC pres-
ervation or amputation. A study on imprint cytological assessment of the subareolar tissue
showed that it might not be sufficient as an exclusive method for the intraoperative assessment
of the NAC, having the sensitivity of 50% and the specificity of 87.58% [36]. The intraoperative
assessment of NAC by frozen sections is more sensitive (92%), but to obtain reliable results it
is needed to use specific diagnostic protocols [37].
In addition, we showed for the first time the feasibility of the HER2 immunostaining in air
dried ND pre-stained smears, and observed a very high concordance with the results obtained
on the immunostaining performed on histological sections of the corresponding surgical sam-
ple. This suggests the possibility to implement this method for studying malignant NDc and to
use the results as an additional biological parameter for guiding NAC surgery.
In conclusion, we observed that malignant NDc influenced surgical decision in our case
series and confirmed that malignant NDc is highly specific for the presence of breast cancer,
mainly DCIS. Finally, we showed that if NDc is HER2 positive, NAC involvement is more
likely than in HER2 negative cases.
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